Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14853, USA.
Am J Hum Genet. 2013 Jul 11;93(1):78-89. doi: 10.1016/j.ajhg.2013.05.022. Epub 2013 Jun 20.
To better understand different molecular mechanisms by which mutations lead to various human diseases, we classified 82,833 disease-associated mutations according to their inheritance modes (recessive versus dominant) and molecular types (in-frame [missense point mutations and in-frame indels] versus truncating [nonsense mutations and frameshift indels]) and systematically examined the effects of different classes of disease mutations in a three-dimensional protein interactome network with the atomic-resolution interface resolved for each interaction. We found that although recessive mutations affecting the interaction interface of two interacting proteins tend to cause the same disease, this widely accepted "guilt-by-association" principle does not apply to dominant mutations. Furthermore, recessive truncating mutations in regions encoding the same interface are much more likely to cause the same disease, even for interfaces close to the N terminus of the protein. Conversely, dominant truncating mutations tend to be enriched in regions encoding areas between interfaces. These results suggest that a significant fraction of truncating mutations can generate functional protein products. For example, TRIM27, a known cancer-associated protein, interacts with three proteins (MID2, TRIM42, and SIRPA) through two different interfaces. A dominant truncating mutation (c.1024delT [p.Tyr342Thrfs*30]) associated with ovarian carcinoma is located between the regions encoding the two interfaces; the altered protein retains its interaction with MID2 and TRIM42 through the first interface but loses its interaction with SIRPA through the second interface. Our findings will help clarify the molecular mechanisms of thousands of disease-associated genes and their tens of thousands of mutations, especially for those carrying truncating mutations, often erroneously considered "knockout" alleles.
为了更好地理解突变导致各种人类疾病的不同分子机制,我们根据遗传模式(隐性与显性)和分子类型(框内[错义点突变和框内缺失]与截短[无义突变和移码缺失])对 82,833 个与疾病相关的突变进行了分类,并系统地在具有原子分辨率界面的三维蛋白质互作网络中检查了不同类别疾病突变的影响,每个相互作用都有分辨率接口。我们发现,尽管影响两个相互作用蛋白相互作用界面的隐性突变倾向于导致相同的疾病,但这种广泛接受的“关联即有罪”原则不适用于显性突变。此外,编码相同界面的区域中的隐性截短突变更有可能导致相同的疾病,即使对于接近蛋白质 N 末端的界面也是如此。相反,显性截短突变倾向于在编码界面之间区域的区域中富集。这些结果表明,相当一部分截短突变可以产生功能性蛋白质产物。例如,已知与癌症相关的蛋白 TRIM27 通过两个不同的界面与三个蛋白(MID2、TRIM42 和 SIRPA)相互作用。与卵巢癌相关的显性截短突变(c.1024delT [p.Tyr342Thrfs*30])位于编码两个界面的区域之间;改变的蛋白质通过第一个界面保留与 MID2 和 TRIM42 的相互作用,但通过第二个界面失去与 SIRPA 的相互作用。我们的发现将有助于阐明数千个与疾病相关的基因及其数万个突变的分子机制,特别是对于那些携带截短突变的基因,这些突变通常被错误地认为是“敲除”等位基因。